Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107150 | 0.89 | PTGER2 (0.38) | S1PR4CHRM3NLRP3MEN1ALDH1A1 | |
| SCHEMBL5106661 | 0.88 | S1PR4 (0.44) | S1PR4CHRM3PDK2LMNA | |
| SCHEMBL5112474 | 0.88 | NLRP3 (0.37) | S1PR4NLRP3PDK2LMNAKMT2A | |
| SCHEMBL5106742 | 0.86 | CHRNA7 (0.39) | S1PR4NLRP3LMNA | |
| SCHEMBL5111878 | 0.84 | SLC6A4 (0.41) | S1PR4NLRP3PDK2LMNA | |
| SCHEMBL5103336 | 0.83 | CHRNA7 (0.44) | CHRM3PDK2MEN1LMNAKMT2A | |
| SCHEMBL5103798 | 0.82 | CHRM3 (0.44) | CHRM3 | |
| SCHEMBL5099275 | 0.82 | IDH2 (0.41) | CHRM3HSD17B10L3MBTL1AKR1C3AKR1C2 | |
| Trifluoroacetic Acid SCHEMBL5100344 | 0.82 | S1PR4 (0.46) | S1PR4HSD17B10L3MBTL1PTPN5PDK2 | |
| SCHEMBL5111908 | 0.80 | NLRP3 (0.39) | S1PR4NLRP3PDK2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | LAINE DRAMANE I | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | S1PR4 547/4885CHRM3 1/4885HSD17B10 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.